Occlude Defect ,
To provide global doctors and patients with safe and innovate medical devices to treat cardiovascular diseases
Being an innovative company, we consistently explore new idea and methods
27th January 2021, LifeTech Scientific Corporation obtained formal written notice from the National Medical Products Administration confirming the admission of Artery Stent Graft System into the NMPA Special Examination and Approval Procedure for Innovative Medical Services.
On 13 January 2021, G-iliac™ iliac artery bifurcation stent graft system, the novel device self-developed by LifeTech Scientific Corporation,has obtained the market registration approval from the China National Medical Products Administration.
On 24 December 2020, LAmbre™Left Atrial Appendage Closure System,developed by LifeTech Scientific Corporation,has obtained the approval by the US Food and Drug Administration for the commencement of an investigator-initiated clinical trial in the US.
The leading company specialized in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases —LifeTech Scientific Corporation (the “Company”) and its subsidiaries (the “Group”) announced the audited consolidated results for the year ended 31 December 2020 (the “Reporting Period”).
On 4 December 2020, LifeTech Scientific Corporation entered into a placement agreement with the Citigroup Global Markets Limited. The Company will place 287,320,000 new shares at the price of HK$3.2368 per placing share.
On 24 November 2020, Biotyx Medical (Shenzhen) Co., Ltd. , a holding subsidiary of Lifetech Scientific，specialized in research, development, manufacture and sales of metal-based bioresorbable medical devices, has successfully introduced series A strategic investors, including IDG Capital and Co-Stone Asset Management.
Lifetech is a leading developer, manufacturer and vendor of advanced minimally invasive medical devices for cardiovascular and peripheral vascular diseases and disorders.
Founded in 1999, we are now the second largest provider of congenital heart defect occluders in the world and the largest provider to BRIC countries.